Yunnan Baiyao Group Co.,Ltd
000538.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$91.71B
Close$
$81.08
52.8% upside
Current Fair Value
52.8% upsideUndervalued by 52.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $91.71 Billion |
|---|---|
| Enterprise Value | $85.71 Billion |
| Dividend Yield | $2.62 (5.10%) |
| Earnings per Share | $2.89 |
| Beta | 0.1 |
| Outstanding Shares | 1,784,262,603 |
Return
| Return on Equity | 12.74% |
|---|---|
| Return on Assets | 9.47% |
| Return on Invested Capital | 11.66% |
Valuation & Multiples
| P/E Ratio | 17.6 |
|---|---|
| PEG | -868.81 |
| Price to Sales | 2.31 |
| Price to Book Ratio | 2.31 |
| Enterprise Value to Revenue | 2.05 |
| Enterprise Value to EBIT | 17.43 |
| Enterprise Value to Net Income | 16 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.09 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 28, 2026
EPS Estimate
$0.99
Average shareholder expectationRevenue Estimate
$10.31 B
Average shareholder expectationNext Earnings Call
Expected Date
October 30, 2026
EPS Estimate
$0.72
Average shareholder expectationRevenue Estimate
$10.19 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Yunnan Baiyao Group Co.,Ltd
9,286 employees
CEO: Ming Dong Operating globally and domestically within China, Yunnan Baiyao Group Co., Ltd. specializes in the pharmaceutical industry. Its diverse portfolio encompasses health supplements, a wide array of medications, medical devices, traditional C...